WallStreetZenWallStreetZen

NASDAQ: ITRM
Iterum Therapeutics PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ITRM

Based on 1 analyst offering 12 month price targets for Iterum Therapeutics PLC.
Min Forecast
$6.00+279.75%
Avg Forecast
$6.00+279.75%
Max Forecast
$6.00+279.75%

Should I buy or sell ITRM stock?

Based on 1 analyst offering ratings for Iterum Therapeutics PLC.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ITRM stock forecasts and price targets.

ITRM stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-01

1 of 1

Forecast return on equity

Is ITRM forecast to generate an efficient return?

Forecast return on assets

Is ITRM forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

ITRM revenue forecast

What is ITRM's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$930.0k
Avg 2 year Forecast
$3.7M
Avg 3 year Forecast
$12.3M

ITRM vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ITRM$1.58$6.00+279.75%Buy
ONCT$8.77$34.00+287.91%Strong Buy
PLUR$5.00N/AN/A
SLGL$0.93$9.00+872.97%Buy
EYEN$0.54$12.00+2,109.94%Buy
View Top Biotech Stocks

Iterum Therapeutics Stock Forecast FAQ

Is Iterum Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: ITRM) stock is to Buy ITRM stock.

Out of 1 analyst, 0 (0%) are recommending ITRM as a Strong Buy, 1 (100%) are recommending ITRM as a Buy, 0 (0%) are recommending ITRM as a Hold, 0 (0%) are recommending ITRM as a Sell, and 0 (0%) are recommending ITRM as a Strong Sell.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.

What is ITRM's revenue growth forecast for 2025-2027?

(NASDAQ: ITRM) Iterum Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Iterum Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast ITRM's revenue for 2025 to be $15,276,909, with the lowest ITRM revenue forecast at $15,276,909, and the highest ITRM revenue forecast at $15,276,909. On average, 1 Wall Street analysts forecast ITRM's revenue for 2026 to be $60,614,833, with the lowest ITRM revenue forecast at $60,614,833, and the highest ITRM revenue forecast at $60,614,833.

In 2027, ITRM is forecast to generate $202,213,711 in revenue, with the lowest revenue forecast at $202,213,711 and the highest revenue forecast at $202,213,711.

What is ITRM's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: ITRM) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is ITRM's Price Target?

According to 1 Wall Street analyst that have issued a 1 year ITRM price target, the average ITRM price target is $6.00, with the highest ITRM stock price forecast at $6.00 and the lowest ITRM stock price forecast at $6.00.

The Wall Street analyst predicted that Iterum Therapeutics's share price could reach $6.00 by Apr 1, 2025. The average Iterum Therapeutics stock price prediction forecasts a potential upside of 279.75% from the current ITRM share price of $1.58.

What is ITRM's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: ITRM) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.